Monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) receptor, or its ligand (PD-L1), have increasingly emerged as a highly efficacious treatment for several cancers, including lung and melanoma. This evidence concerns the gene PDCD1 and melanoma.